1. Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer R, DeVita VT, Myers CE. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980;40:567–572.
2. Markman B, Reichman B, Hakes T, Hoskins W, Rubin S, Jones W, Lewis JL Jr. Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: The Memorial Sloan Kettering Cancer Center Experience. JAMA 1989;16:65–67.
3. Howell SB, Pfeifle CG, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845–851.
4. Bertoglio S, Melioli G, Baldini E, Catturich A, Sertoli MR., Civalleri D, Percivale P, Meier W, Galazka A, Badellino F. Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer. Acta Med Austriaca 1989;16:81–83.
5. Raeth U, Schmid H, Karck U, Kempeni J, Schlick E, Kaufmann M. Phase-II-trial of recombinant human tumor necrosis factorta (rHuTNF) in patients with malignant ascites from ovarian carcinomas and non-ovarian tumors with intraperitoneal spread. Proc Am Soc Clin Oncol 1991; 10:187.